INZY

Inozyme Pharma
INZY

Overview Fund Activity
Delisted

INZY was delisted on the 30th of June, 2025.

Back to rankings

51 hedge funds and large institutions have $118M invested in Inozyme Pharma in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 14 reducing their positions, and 9 closing their positions.

Holders
51
Holders Change
-1
Holders Change %
-1.92%
% of All Funds
0.79%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
8
Increased
17
Reduced
14
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
O
1
OrbiMed
New York
$3.59M
2
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$10.9M
3
Janus Henderson Group
3
Janus Henderson Group
United Kingdom
$857K
4
BCM
4
Bridgeway Capital Management
Texas
$528K
5
Jacobs Levy Equity Management
5
Jacobs Levy Equity Management
New Jersey
$606K

Top Sellers

1
Wellington Management Group
1
Wellington Management Group
Massachusetts
$0
2
Russell Investments Group
2
Russell Investments Group
United Kingdom
$0
3
Vanguard Group
3
Vanguard Group
Pennsylvania
$3.33M
4
Commonwealth Equity Services
4
Commonwealth Equity Services
Massachusetts
$0
5
BlackRock
5
BlackRock
New York
$5.71M
Name Market Value Shares Shares
Change 		Shares
Change %
NMC
1
NEA Management Company
Maryland
$16.7M 2,444,379 – –
DM
2
Deerfield Management
New York
$16M 2,344,786 – –
SI
3
Sofinnova Investments
California
$13.8M 2,028,308 – –
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$10.9M 1,599,028 +131,200 +9%
PBPIA
5
Pivotal bioVenture Partners Investment Advisor
California
$10.9M 1,591,154 – –
SCM
6
Suvretta Capital Management
New York
$6.91M 1,013,216 +26,816 +3%
CA
7
CHI Advisors
New York
$6.08M 892,057 -28,207 -3%
RSCM
8
Rock Springs Capital Management
Maryland
$5.92M 868,466 +18,451 +2%
BlackRock
9
BlackRock
New York
$5.71M 836,998 -63,721 -7%
Fidelity Investments
10
Fidelity Investments
Massachusetts
$4.16M 609,380 – –
O
11
OrbiMed
New York
$3.59M 526,600 +232,600 +79%
Vanguard Group
12
Vanguard Group
Pennsylvania
$3.33M 488,719 -122,466 -20%
JPMorgan Chase & Co
13
JPMorgan Chase & Co
New York
$2.21M 324,387 -7,504 -2%
MB
14
MPM BioImpact
Massachusetts
$2.06M 302,615 -18,109 -6%
State Street
15
State Street
Massachusetts
$1.28M 187,102 -1,165 -0.6%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$1.26M 184,019 -14,605 -7%
Janus Henderson Group
17
Janus Henderson Group
United Kingdom
$857K 125,153 +125,153 New
Northern Trust
18
Northern Trust
Illinois
$823K 120,762 +4,661 +4%
CCM
19
CAAS Capital Management
New York
$771K 113,091 -22,307 -16%
BBA
20
Baker Bros. Advisors
New York
$730K 106,999 – –
Citadel Advisors
21
Citadel Advisors
Florida
$729K 106,978 +12,512 +13%
Jacobs Levy Equity Management
22
Jacobs Levy Equity Management
New Jersey
$606K 88,921 +67,884 +323%
BCM
23
Bridgeway Capital Management
Texas
$528K 77,400 +77,400 New
Bank of New York Mellon
24
Bank of New York Mellon
New York
$281K 41,196 +778 +2%
Nuveen Asset Management
25
Nuveen Asset Management
Illinois
$251K 42,261 -5,401 -11%
1
2 3